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ABSTRACT 
Objective: To evaluate the isoquinoline (N-substituted (E)-4-arylidene-isoquinoline-1,3-dione) derivatives (5a-h) for their anti-inflammatory, 
analgesic and antipyretic activity potentials in animal models using indomethacin and diclofenac sodium as the standard. 
Methods: Peripheral and central analgesic activities were determined by induced writhing and tail immersion tests. Carrageenan stimulated rat 
paw edema model was used to evaluate the anti-inflammatory activities by examining the increase in paw volume and percentage inhibition of paw 
volume was calculated with plethysmometer at different time periods. Brewer’s yeast induced pyresis model was used to assessing the anti-pyretic 
activity by measuring the decreased rectal temperature.  
Results: Compounds 5g>5d>5h showed anti-inflammatory, analgesic and antipyretic activities and they were significant with p<0.001 and 
comparable with the control group. The results coincided with our previous report which suggests that the compounds 5g>5d>5h may take into 
further druggability evaluations.  
Conclusion: New isoquinoline derivatives produced significant anti-inflammatory, analgesic, and antipyretic activities and this suggests that these 
derivatives need further drug development evaluations especially for the compounds 5g>5d>5h. 
Keywords: N-substituted (E)-4-arylidene-isoquinoline-1,3-dione, Carrageenan, Anti-inflammatory, Analgesic, Diclofenac sodium, Antipyretic, 
Indomethacin 
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INTRODUCTION 
Inflammation is a common and serious predicament in cases of 
hypersensitivity, autoimmune diseases, and negative response of 
transplanted organs [1]. Healing alternatives for inflammatory 
diseases generate unfavourable effects and being evidence being 
deficient in effectiveness. Non-steroidal anti-inflammatory drugs 
(NSAIDs) are precious in the healing of severe and persistent 
inflammation [2], fever [3], and pain [4] but long-term use of NSAIDs 
is related through the gastrointestinal wound, hemorrhage, and 
nephrotoxicity [5]. A number of isoquinoline alkaloids were 
reported for anti-inflammatory activity [6, 7]. We already have 
evaluated the in vitro anti-inflammatory [8], anticancer [9] 
properties of the proposed compounds. In this report, the in vivo 
anti-inflammatory, analgesic, and antipyretic potentials were 
evaluated and reported as mentioned in our previous report [8].  
MATERIALS AND METHODS  
Chemicals  
λ-Carrageenan was procured from Sigma (St Louis, MO), Diclofenac 
Sodium was a legacy sample from Blessing Pharmaceuticals India 
(Maharashtra, India), Indomethacin and Brewer’s yeast from Sigma-
Aldrich Chemicals, USA and all other chemicals & reagents were 
used analytical grade. The test compounds (E)-4-arylidene 
isoquinoline-1,3-diones derivatives 5(a–h) were synthesized and 
reported previously [8] was taken for animal studies. 
Chemical compounds for animal studies  
A mixture of homophthalic acid (1) and substituted anilines (2a-c) 
(1:1 ratio) in toluene and 5 mol % ZnO were amended to the 
suspension and refluxed. The obtained pale yellow solid compounds 
N-substituted homopthalimides (3a-c) were purified and 
characterized by FT-IR, GC-MS, 1H NMR and [13]C NMR. 
Condensation of aromatic aldehydes (4a-c) with 3a-c in ethanol 
using oxalic acid as a catalyst to obtain the (E)-4-arylidene 
isoquinoline-1,3-diones derivatives 5(a–h).  
Animals  
Wistar albino rats of either sex, 50-100g, were procured from the 
animal house, Annamalai University, India. They were in a controlled 
room with a 12 h dark-light cycle and fed with commercial pellet feed 
from Hindustan Lever Ltd. (Mumbai, India); water was freely available. 
The animal model study was approved (Vide No.1038, 2013) by the 
Institutional Animal ethics committee of Annamalai University, India 
and was conducted in accordance with the “Guidelines for care and 
Use of Laboratory Animals", Government of India.  
Test of peripheral analgesic activity by acetic acid-induced 
writhing response 
The acetic acid-induced writhing test was carried out in accordance 
with Collier et al. [10]. The rats were intraperitoneally injected with 
0.6 % acetic acid (10 ml/kg b. wt) to elicit a writhing response. 
Immediately after the administration of acetic acid, the animals were 
placed in glass cages, and the number of writhes was recorded for the 
following 30 min. A considerable reduction in the number of writhes 
by drug treatment as compared to control animals was considered as a 
positive analgesic response. Test compounds (50 and 100 mg/kg) and 
diclofenac sodium (50 mg/kg b. wt) were administered 
intraperitoneally 30 min before the acetic acid injection. Mean 
writhing and average protection values were calculated.  
Test of central analgesic activity of p-CA (p-Coumaric acid) by 
tail-immersion test 
The tail-immersion test was carried out as described by Janssen et 
al. 1963, was immersed in a water bath thermostatically maintained 
at 55±1 °C [11]. The time in seconds for the tail withdrawal from the 
water was taken as the tail withdrawal latency or reaction time, with 
a cut-off time of immersion set at 10 seconds. The reaction time was 
measured before drug treatment at 15, 30, 45 and 60 min after the 
drugs were administered. Test compounds (50 and 100 mg/kg) and 
diclofenac sodium (50 mg/kg b. wt) were administered at a lower 5-
cm portion of the tail. Writhing values and average protection 
percentage values were calculated and tabulated.  
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Acute toxicity studies 
According to OECD guidelines, the acute toxicity was carried out 
[12]. The wistar rats (100±10 gm) either sex were used for this 
study. The animals were divided into four groups in which each 
group with three animals (n=3). The animals fasted overnight and 
test compounds were given orally to rats at a dose of 15, 30 and 45 
mg/kg body weight. There was continued observation for the 
behavioral changes for first three hours and for mortality at the end 
of 24 h. The animals were examined daily up to 8-10th day for the 
behavioral change or mortality. 
In vivo anti-inflammatory activity–carrageenan-induced rat 
paw edema method 
Wistar rats (100±10 gm) of either sex were used. Animals were 
weighed and randomized in 5 groups (n=6). Before treatment, the 
volume of the right paw of each animal was determined using a 
plethysmometer (UGO Basile, 7140). All the animals were starved 
for 12 h. To ensure, uniform hydration, the rats received 5 ml of 
water by stomach tube. Group I served as control (Vc) and do not 
receive any drug. Group II received the standard Indomethacin (10 
mg/kg, p. o), and Group III to VI was received test compounds (5a-
h) in different doses (50 and 100 mg/kg). 30 min later, the rats 
were challenged by a subcutaneous injection of 0.1 ml of 1% w/v 
freshly prepared a solution of λ-carrageenan in saline into the 
plantar side of the left hind paw. The paw was marked with ink at 
the level of the lateral malleolus and immersed in the water 
reservoir of digital Plethysmometer up to that mark to measure 
the paw volume. The paw volume (Vt) was measured at 2, 4, 6, 12 
and 24 h immediately after carrageenan injection in control, 
compound 5a-h treated and indomethacin-treated groups [13]. 
The % of inhibition of each group was determined using the 
following formulae:  
 
Where, Vc stands for mean variation of edema for the control group; 
Vt equals mean variation of edema. 
Antipyretic activity  
Wistar strain rats of either sex weighing 100±10 gm were taken, and 
animals were fasted overnight and divided into different groups 
(n=6). Fever was induced by injecting 20 ml/kg (s. c) of 20% 
suspension of Brewer's yeast in normal saline below the nape of the 
neck, and the initial rectal temperature was recorded.  
After 18 h, animals that showed an increase of 0.3-0.5 °C in rectal 
temperature were selected for the experiment. The test compounds 
(50 and 100 mg/kg), standard indomethacin (10 mg/kg) and control 
0.1% sodium CMC was administered orally. The rectal temperature 
was measured every 30 min up to 120 min after compounds 
administration [14].  
Statistical analysis  
All biological in vitro and in silico experiments results were 
expressed as percentage decrease with respect to control values and 
compared by one-way ANOVA with Dunnett’s post test was 
performed. GraphPad Prism version 6.07 for Windows, GraphPad 
Software, San Diego California USA, www. graphpad. Com was used 
for statistical analysis. A difference was considered statistically 
significant if p≤0.05.  
RESULTS  
Synthesis of (E)-4-arylidene isoquinoline-1,3-diones derivatives  
All synthesized derivatives appeared as yellow solid and the 
chemical yield of the new compounds N-aryl homo phthalimide 
derivatives (3a-c) and (E)-4-arylidene isoquinoline-1,3-dione 
derivatives (5a-h) was calculated. The spectral confirmations of 
compounds 5a-h obtained were reported along with the in vitro 
evaluations in our previous report [8]. The purified compounds 
were taken for animal studies which were prepared in various 
doses 50–200 mg/kg. The product yield and time is taken for 
completions of reaction along with starting ingredients were 
depicted in table 1 and 2. 
  
Table 1: Synthesis of N-aryl homo phthalimide derivatives 
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Result of peripheral analgesic activity by acetic acid-induced 
writhing response 
In the acetic acid-induced writhing test, the standard diclofenac 
sodium showed significant peripheral analgesic activity in a dose-
dependent manner, and compound 5g and 5h showed equal 
activities to diclofenac sodium. Intraperitoneal injection of acetic 
acid in rats significantly increased the writhing. Among all the rest 
compounds, 5d showed a moderate activity when to compare with 
the diclofenac sodium, 5g and 5h (table 3). 
Result of central analgesic activity of p-CA (p-Coumaric acid) by 
tail-immersion test 
Table 4 below depicts the central analgesic activity of diclofenac 
and the test compounds as measured by the tail-immersion test 
administered with p-CA (p-Coumaric acid). Diclofenac (50/100 
mg/kg b. wt) exhibited significant analgesic activity in a dose-
dependent manner by delaying the tail withdrawal latency or 
reaction time, compared to the control group. Diclofenac 
treatment was found to have a better effect compared to all 
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tested compounds. Among all the compounds, 5d and 5g showed 
almost equal activity when to compare with the diclofenac 
sodium and 5h showed a moderate. The least activity was 
showed by 5b (table 4). 
 
Table 2: Synthesis of (E)-4-arylidene isoquinoline-1, 3-dione derivatives 
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Table 3: Effect of diclofenac and compounds 5a-h on writhing response test in rats 
Test samples Dose Mean writhing (X±SE) Average protection (%) 
Control -  28.0±1.55 – 
Diclofenac sodium 50 mg/kg 3.00±2.44** 76.00±6.54 








































Data represent mean values±SE n=6, compared with the control group. **statistical significance when p<0.05 
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Table 4: Effect of diclofenac and compounds 5a-h on tail-immersion test 
Test samples Dose Mean latency time (X±SE) Average protection (%) 
Control - 28.0±1.55 – 
Diclofenac sodium 50 mg/kg 3.40±2.44** 78.00±4.98 








































Data represent mean values±SE n=6, compared with the control group. ** Statistical significance when p<0.05 
 
Acute toxicity study results  
Results of acute toxicity study showed that there was no mortality or 
any significant change in the behavior of the mice recorded up to the 
dose of 200 mg/kg of the tested compounds (5a-h). Based on the 
results of the preliminary toxicity testing, the doses of the 
compounds for further studies were decided to be 10, 50 and 100 
mg/kg body weight of the rats. 
Carrageenan-induced paw edema  
Anti-inflammatory effect of Isoquinoline (N-substituted (E)-4-
arylidene-isoquinoline-1,3-dione) derivatives (5a-h) were shown in 
table 2. From the observations, compounds 5d, 5g, and 5h have 
significant (P<0.05) anti-inflammatory activity when compared with 
the control. The average percentage inhibition in paw edema after 2 
h was recorded as 78±4.24 for indomethacin and 70±3.88, 76±2.88, 
and 74±4.24 for 5d, 5g and 5h respectively. The least activity was 
found for 5a, 5b, and 5f with 38±4.64, 32±4.24 and 34±3.54 
respectively. A moderate activity found for 5e with 64±5.44 which 
shows the close enough potency to compete with the top ranked 
compounds here (table 5). 
Brewer’s yeast induced pyrexia  
The tested rats exhibited a mean raise of about 1 °C in rectal 
temperature 1 h after Backer’s yeast injection (135 mg/kg, i. p). The 
test compounds (5d and 5h) produced significantly (p<0.05) 
antipyretic activity at 2, 3, 4 and 5 h, whereas test compound 5g and the 
reference drug Paracetamol (150 mg/kg) showed significant antipyretic 
activity throughout the observation period up to 5 h (fig. 1). 
 
 
Fig. 1: Antipyretic activity results for compounds 5a-h, 
paracetamol as ref. drug 
  
 Table 5: Effect of Indomethacin (standard) and compounds 5a-h on carrageenan-induced rat paw edema 
Group Dose Edema volume in ml 
½ hr 1 hr 1½ hr 2 hr mean±SD % reduction 
Control 5 ml/kg 0.38±0.01 0.37±0.02 0.40±0.01 0.38±0.01 - 
Standard 10 mg/kg 0.22±0.02 0.16±0.01* 0.15±0.01* 0.13±0.01* 78±4.24* 
5a 50 mg/kg 0.54±0.01 0.48±0.01* 0.40±0.01* 0.38±0.01* 38±4.64** 
100 mg/kg 0.47±0.02 0.39±0.01* 0.36±0.01* 0.35±0.01* 
5b 50 mg/kg 0.48±0.01 0.45±0.01* 0.43±0.01* 0.46±0.01* 34±3.54** 
100 mg/kg 0.47±0.02 0.41±0.01* 0.40±0.01* 0.44±0.01* 
5c 
 
50 mg/kg 0.38±0.01 0.35±0.01* 0.33±0.01* 0.44±0.01* 42±3.86** 
100 mg/kg 0.37±0.02 0.31±0.01* 0.27±0.01* 0.42±0.01* 
5d 50 mg/kg 0.28±0.01 0.22±0.01* 0.20±0.01* 0.17±0.01* 70±3.88* 
100 mg/kg 0.27±0.02 0.18±0.01* 0.17±0.01* 0.16±0.01* 
5e 50 mg/kg 0.38±0.01 0.25±0.01* 0.23±0.01* 0.17±0.01* 64±5.44* 
100 mg/kg 0.37±0.02 0.21±0.01* 0.17±0.01* 0.16±0.01* 
5f 50 mg/kg 0.58±0.01 0.50±0.01* 0.48±0.01* 0.42±0.01* 32±4.24** 
100 mg/kg 0.50±0.02 0.48±0.01* 0.42±0.01* 0.40±0.01* 
5g 50 mg/kg 0.22±0.01 0.20±0.01* 0.18±0.01* 0.14±0.01* 76±2.88* 
100 mg/kg 0.20±0.02 0.17±0.01* 0.14±0.01* 0.12±0.01* 
5h 50 mg/kg 0.26±0.01 0.22±0.01* 0.18±0.01* 0.16±0.01* 74±4.24* 
100 mg/kg 0.24±0.02 0.20±0.01* .17±0.01* .14±0.01* 
mean±SEM n=6, (one-way ANOVA), statistically significant from control *p<0.001, **not significant 
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Isoquinoline (N-substituted (E)-4-arylidene-isoquinoline-1, 3-dione) 
derivatives (5a-h) were evaluated for anti-inflammatory, analgesic and 
antipyretic activity by using standard experimental models. In the 
present investigation carrageenan-induced paw edema acute 
inflammatory model, isoquinoline derivatives inhibited inflammation 
efficiently by cyclooxygenase inhibition. COX (Cyclooxygenase) was 
alleged to be expressed constitutively with constant levels in individual 
tissues [15]. Prostaglandin synthesis was thought to increase in 
inflammation because of increased release of precursor [16]. COX 
activity increases in inflammation, and this increase can be 
prohibited by corticosteroids [17]. This is caused by the compounds 
may show anti-corticosteroid activity. Both the COX inhibition 
results and in vitro anti-inflammatory results coincided together for 
the compounds 5d, 5g and 5h. Acute inflammation is supposed to be 
biphasic, the first phase (1hr) involves the release of serotonin and 
histamine while the second phase (over 1 hr) is mediated by 
prostaglandins, the cyclooxygenase products and continuity 
between two phases is proved by kinins [18-20]. Among all the 
derivatives 5d, 5g and 5h at 100 mg/kg dose showed significant paw 
edema inhibition and this activity of isoquinoline derivatives. In the 
assessment of analgesic activity, the mechanical stimulations can 
suggest the pain by raising the synthesis of pain mediators (PG’s, 
histamine, kinins, etc. [21] through pain receptors and the reaction 
time is noted as a therapeutic end point. This suggests that the 
compounds have proved inhibitory actions on cyclooxygenase 
reconciled pathway. In Brewer’s yeast induced pyrexia model, 
evaluation in the body temperature is due to the fever mediators 
such as IL-Ib, IL-6, IFN-α and prostaglandins (PGE2), especially in 
the brain regions. The isoquinoline derivatives showed bradykinin 
and peptide synthesis inhibition [22]. As compared with other 
derivatives 5d, 5g, and 5h were shown a reduction of body 
temperature at 100 mg/kg when compared with control.  
CONCLUSION  
In conclusion, the new isoquinoline derivatives produced significant 
anti-inflammatory, analgesic, and antipyretic activities and this suggests 
that these derivatives have keen inhibitory actions on cyclooxygenase 
enzymes also the work may be extended to further drug development 
evaluations especially for the compounds 5g>5d>5h.  
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